Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: A randomized controlled trial
William G Petchey, Ingrid J Hickman, Johannes B Prins, Carmel M Hawley, David W Johnson, Nicole M Isbel
NEPHROLOGY | WILEY | Published : 2013
AIM: To assess the impact of vitamin D supplementation (cholecalciferol) on the insulin sensitivity and metabolic health of patients with chronic kidney disease (CKD). METHODS: Twenty-eight adult patients with CKD stages 3-4 were recruited from the outpatient department of the Princess Alexandra Hospital (Brisbane, Australia) to a double-blind randomized trial of cholecalciferol (vitamin D3) 2000 IU/day or placebo for 6 months. Metabolic parameters at baseline were compared with 20 non-CKD adults. The primary outcome was an improvement in insulin resistance (glucose disposal rate, GDR) at 6 months (quantified by hyperinsulinaemic euglycaemic clamp). Carbohydrate and lipid oxidation rates wer..View full abstract
This study was supported by a peer-reviewed competitive research grant from Roche Pharmaceuticals, Australia and a Private Practice Research Grant from the Princess Alexandra Foundation, Brisbane, Australia. WGP is supported by scholarships from the University of Queensland and the Department of Nephrology, Princess Alexandra Hospital (Brisbane, Australia), and has received honoraria from Shire, Australia. DWJ is supported by a Queensland Government Health Research Fellowship. The authors would like to thank A/Prof. Jonathon Whitehead, Dr David Vesey and Dr John Cardinal for their assistance with sample analysis, Julianne Wilson, Karen Sonnenburg and Markus Pitkin for their nursing expertise during patient visits, and Eryn Murray, Linda Orazio and Megan Rossi for their dietetic input. The authors would also like to thank the Centre for Clinical Research Excellence - Cardiovascular Diseases and Metabolic Disorders (University of Queensland, Brisbane, Australia) for resource assistance.